Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+BL and pre‐B‐ALL
Publisher： John Wiley & Sons Inc
E-ISSN： 1365-2141|171|5|763-775
ISSN： 0007-1048
Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.171, Iss.5, 2015-12, pp. : 763-775
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
